M&A: Health Catalyst Closes $147M Sale of Vitalware to Med-Metrix
Health Catalyst, Inc. said it closed the July 31, 2026 sale of Vitalware, LLC to Med-Metrix, LLC. The divestiture generated $147M in total cash consideration, subject to adjustments. Health Catalyst plans to use proceeds and cash on hand to fully repay its credit facility, removing about $19M in annual GAAP interest expense, and to focus on its core healthcare intelligence and AI platform.
How this was made
The 30-second read
Why it matters
The transaction provides $147M cash consideration, which the company combines with existing cash to fully repay and retire its credit facility, eliminating roughly $19M in annual GAAP interest expense and increasing financial flexibility for its AI-focused core platform strategy.
Market read
Traders can reassess HCAT’s leverage/interest expense outlook and strategic focus following a completed, cash-funded divestiture.
What to watch
The article notes customary adjustments and regulatory closing conditions for the buyer, but does not quantify deal-related one-time costs, tax impacts, or how quickly the AI roadmap will translate into incremental revenue.
Background
Health Catalyst completed the divestiture of Vitalware, its mid-revenue cycle business, to Med-Metrix on July 31, 2026.
Ticker impact
Health Catalyst closed the $147M sale of Vitalware to Med-Metrix and will use proceeds to fully repay its credit facility, removing about $19M annual GAAP interest expense.
Near-term upside bias from reduced leverage/interest expense and clearer focus, with follow-through dependent on execution of the AI platform strategy.
The article provides concrete transaction economics ($147M cash), a specific cost reduction (~$19M annual GAAP interest), and stated capital redeployment toward the core platform.
Market effects
Signals continued portfolio reshaping among healthcare analytics/software firms, with capital rotation toward AI-enabled core platforms.
Limited direct regional spillover; primarily impacts US-listed healthcare software sentiment.
Low global relevance beyond healthcare IT M&A and financing conditions.
Counterpoint
Removing interest expense helps, but divesting a ~$37M FY2025 revenue unit could pressure top-line growth if the core AI platform monetization ramps slower than expected.
Key entities
- companyHealth Catalyst, Inc.
Healthcare intelligence company that closed the Vitalware sale and plans to redeploy proceeds toward its core analytics and AI roadmap.
- business_unitVitalware, LLC
Mid-revenue cycle business divested by Health Catalyst.
- companyMed-Metrix, LLC
Buyer of Vitalware for $147M in cash.
